BMYMP News and Press, Bristol-Myers Squibb $2Pr From 04/25/24

2024-04-25 13:11:06 ET Bristol-Myer Squibb Company (BMY) Q1 2024 Earnings Conference Call April 25, 2024, 8:00 AM ET Company Participants Tim Power - Vice President, Investor Relations Chris Boerner - Board Chair and Chief Executive Officer David Elkins - Executi...

2024-04-22 00:41:39 ET Summary SCHD is a great capital gains storage for positions that may be getting over-concentrated in your portfolio. Many investors have big winners from buying the dips in 2020 and 2022. Chances are your winners have expanded P/E ratios. SCHD is a great...

2024-04-17 11:30:43 ET Summary Bristol-Myers Squibb Company stock continues to struggle at a four-year low. Revlimid's revenue decline and increased competition from generics pose significant challenges for the company. Bristol-Myers Squibb needs to convince investors that its...

2024-04-12 05:11:48 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2024-04-08 03:22:22 ET Summary The stock market shrugged off rising interest rates and global unrest to produce strong gains during 2023. The DGI for the DIY portfolio also managed double-digit gains for the year. Dividend income grew by 7.9%, lagging the double-digit portfoli...

2024-04-01 03:44:47 ET Summary I rank a selection of Dividend Radar stocks and present the ten top-ranked stocks for consideration. To rank stocks, I do a quality assessment and sort stocks by quality scores, breaking ties with additional metrics. This month, I'm presenting ca...

2024-03-28 16:59:39 ET Summary Bristol Myers Squibb's market capitalization has declined significantly due to the impending expiration of patents for its flagship drugs. Bristol Myers Squibb's high debt levels add to the financial strain, requiring strategic measures to survive an...

2024-03-20 04:50:32 ET Summary Shares of biotechnology companies have been lagging behind the S&P 500 Index. This underperformance of XBI relative to the S&P 500, however, has only made the opportunity even more attractive to us. Evidence of improving fundamentals and ...

2024-03-19 02:19:36 ET Summary Positive safety and anti-tumor activity released from phase 1 portion of phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors. Additional expansion cohort results from the phase 2 portion of the phase 1/2a stud...

2024-03-18 12:28:56 ET Summary Schwab U.S. Dividend Equity ETF™ has undergone a major change in its holdings, eliminating and replacing 23 stocks contributing 1/5 of its dividend. Four of the added stocks are flagged as very risky by Seeking Alpha's Quant rating system...